| 证券代码 | VIST.O |
| 证券名称 | Visterra Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | - |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | Stifel Nicolaus & Company, Incorporated,Leerink Partners LLC |
| 货币单位 | - |
| 公司名称 | Visterra, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | One Kendall Square, Suite B3301, Cambridge, Massachusetts, USA |
| 成立日期 | 2007-12-20 |
| 董事会主席 | Alan L. Crane |
| 公司属地 | United States 美国 |
| 公司网址 | www.visterrainc.com |
| 电话 | +1 (617) 498-1070 |
| 传真 | +1 (617) 498-1073 |
| 公司简介 | Visterra, Inc. is a clinical-stage biopharmaceutical company focused on applying their novel Hierotope(R) platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases. Its platform enables it to address the significant unmet need for effective therapies to prevent and treat infectious diseases caused by organisms that have a high degree of diversity among strains, frequent mutations and a high prevalence of treatment resistance. Its platform also enables it to design and engineer antibody-based biological product candidates for the treatment of non-infectious diseases that are not being adequately addressed with conventional treatment approaches. |